Lupin surges on getting approval from USFDA for Darunavir Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 742.45, up by 19.85 points or 2.75% from its previous closing of Rs. 722.60 on the BSE.
The scrip opened at Rs. 722.65 and has touched a high and low of Rs. 750.00 and Rs. 712.30 respectively. So far 219095 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 979.25 on 13-Oct-2021 and a 52 week low of Rs. 583.05 on 25-May-2022.
Last one week high and low of the scrip stood at Rs. 750.00 and Rs. 645.00 respectively. The current market cap of the company is Rs. 33693.66 crore.
The promoters holding in the company stood at 47.10%, while Institutions and Non-Institutions held 41.45% and 11.45% respectively.
Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Darunavir Tablets, 600 mg and 800 mg, a generic equivalent of Prezista Tablets of Janssen Products, LP.
The company is the exclusive first filer for 800 mg tablets and is eligible for 180-day exclusivity. Lupin will also potentially have shared 180-day exclusivity on the 600 mg tablets. The product will be manufactured at Lupin’s facility in Nagpur, India.
Darunavir Tablets, 600 mg and 800 mg, (RLD Prezista) had estimated annual sales of $343 million in the U.S. (IQVIA MAT June 2022).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
